Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Oct 31, 2022 8:52am
97 Views
Post# 35059612

RE:A concern?

RE:A concern?SPCEO1, this would make no sense and would be a terrible idea.  THTX just told us on the conference call a few weeks ago that they had enough cash for a year.  Plus, they have a pathway via the loan to unlock more cash.  Furthermore, it was stated that they expect to see efficacy from at least one cancer type soon.  Selling more shares at this price would be a flip flop of what we heard on the conference call and would definitely send a negative signal.  

I'm not sure what's worse, partnering too early and not getting paid the highest premium or diluting the company now in order to gain a larger cash reserve.  I can imagine institutional investors would like to see more cash on hand with future clinical trials likely, but THTX has communicated they have the cash they need for the foreseable future.

SPCEO1 wrote: I have heard THTX had good meetings with major shareholders post their third quarter results. Should any of those shareholders want to pickup additional shares of THTX, they would likely only do so through an offering. Could THTX sell shares to them via the ATM facility at these low prices. We know companies always find it pretty difficult to turn down alluring new money like this. I would be interested to know how people here feel about such a development should it occur. It would be good to let the company know before they pull the switch on such a deal if they are indeed considering it. We should have a voice in such a decision and we should let them hear it. Now, I am just speculating based on rather narrow info, but I suspect this is a risk. So, let's just assume a deal at $2 per share for 5 million new shares raising the company a new $10 million in equity capital just for argument's sake. 

To me, doing such a deal would be quite worrisome as it would seem to indicate the data on TH-1902 is not looking good enough to hold off and do a deal once that data is available. Or, perhaps it indicates the phase 1b is going to take a lot longer than they are currently intimating and they need to boost the cash coffers to bridge until they get there. 

On the positive side, we would likely get a new analyst report from Cantor if the ATM  was used. But what can a new analyst say before we get phase 1b info.


<< Previous
Bullboard Posts
Next >>